Vanguard Investments Australia
IMNM icon

Vanguard Investments Australia’s Immunome IMNM Stock Holding History

Vanguard Investments Australia’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$496K Hold
23,407
– – ﹤0.01% 1664
2026
Q1 		$512K Buy
+23,407
New +$521K ﹤0.01% 1557

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vanguard Investments Australia's IMNM Position: Q2 2026 in Review

Vanguard Investments Australia held its Immunome (IMNM) position steady in Q2 2026 at 23,407 shares worth $496K. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

Vanguard Investments Australia first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. The position peaked at $512K in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Vanguard Investments Australia held 23,407 shares of Immunome worth $496K as of Q2 2026.
  • Vanguard Investments Australia left its Immunome share count unchanged in Q2 2026.
  • Immunome made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1664 holding.
  • Vanguard Investments Australia first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Investments Australia's Immunome position peaked at $512K in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.